CCIT-DK: National Center for Cancer Immune Therapy

🆕 Nationwide real-world (DAMMED 🇩🇰) study comparing Dab/Tram vs Enco/Bini in 751 pts with BRAFm metastatic melanoma. ⚖️ No differences in efficacy 🧩 Consistent across subgroups (incl. 🧠 mets) 📄 doi.org/10.1093/jnci/d… In @JNCI_Now @CCITdk @DoniaMarco #Melanoma #Oncology

@CCITdk is happy to support the candidacy of Professor @ulassen to this important post at ESMO @myESMO

Acquired resistance to Cancer Immunotherapy Free at bit.ly/4jptfZz ➡️ Metastatic cancers can be cured ➡️ Pts who initially respond can develop resistance (up to 65% of responders) ❗One of the top priorities in Oncology Reviewed in @TrendsMolecMed @CCITdk @MdCurioni

New #JITC article: Arginase-1-specific T cells target and modulate tumor-associated macrophages bit.ly/3PZKkMP @marper2323 @CCITdk

🎉Cell Therapy Milestone 👍This week, a patient with melanoma received the first non-viral CRISPR-edited TIL infusion product at @CCITdk Congrats to Cell Therapy team @ozcan_met: from preclinical pubmed.ncbi.nlm.nih.gov/35141398/ to GMP grade clinicaltrials.gov/study/NCT06783…

📢 Check out this special case report by Monberg, Svane & colleagues @CCITdk @helsinkiuni @Rigshospitalet 🇩🇰🇫🇮. 💉Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. Available #OpenAccess 👇esmoiotech.org/article/S2590-…

📣 PhD course "Cancer Immunology and Immunotherapy", 4th edition 📃 Course Description and registration 👉bit.ly/40vh1YI ▶WHEN: 07-11/04/2025 (mon-fri) ▶WHERE: Copenhagen Area, Denmark 📩 Full program available soon! Previous edition at bit.ly/3CoqXcB

📢The Copenhagen Symposium on T Cell Therapy and Cellular Engineering (CATC) 2024 ⏰ 24-25 September 2024 📍 Greater Copenhagen, Denmark More at catc.dtu.dk/about

New publication on #MPNsm from @CCITdk published in @BrJHaem: Peripheral blood lymphocytes (PBL) from patients with CALR mutant #MPNsm display increased levels of surface TGFb and GARP. Probably mediated by enhanced binding of activated platelets to PBL. doi.org/10.1111/bjh.19…

📣 Webinar "Adoptive cell immunotherapies for cancer" SN Oncology Webinar Series on 14 May at 4 pm CEST by @SpringerNature 👉 Free registration at: cassyni.com/events/Y5qVZUY… 👩‍🔬 Speaker: Inge Marie Svane, Director of @CCITdk 👨‍🎓 Chair: Luca Danelli, Senior Editor @NatureComms

💬 Fantastic keynote lecture by Dr. Inge Marie Svane from @CCITdk on TIL therapies at VHIO under the framework of #PragamTIL Annual Meeting.

Despite manufacturing costs ~67 000 €, academic TIL therapy for patients with #melanoma is both cost-saving and cost-effective in 🇩🇰 and 🇱🇺 Publicly-funded #celltherapy can be sustainable!

Excited to share our latest article on @jitcancer, where we show that a TGFβ-based immune modulatory vaccine can both directly and indirectly modulate the phenotype of TAMs and CAFs, two high TGFβ-secreting cell subsets in the TME ➡ lnkd.in/dpyf9MPJ @CCITdk

New #JITC review: Biomarkers for response to TIL therapy: a comprehensive review bit.ly/43g4Yhe @Vic_albarran @pballestin @DoniaMarco

📣 The Neoantigen Based Cancer Vaccine Pipeline at Dana Farber Cancer Institute 👨‍⚕️ by Derin Keskin bit.ly/42KN3yY 🕰 March 8th 2024 at 9.15 📍 Auditorium H2, Herlev Hospital, DK 💻Online at bit.ly/4bK1Lug ‼️Join this seminar, No registration required‼️

🔬 Murine Models for Cancer Immunotherapy, an analysis of tumor microenvironment (TME) compositions 🐭 Insights into comparative roles of the Lymphoid, Myeloid, and Stromal cell compartments of these models from the TSMI group here in @CCITdk More at 👉 frontiersin.org/articles/10.33…

Harnessing neoantigen-specific T cells for precision cancer immunotherapy 👉 @NatRevClinOncol, Jan 2024, free access link at rdcu.be/dwp89 💬 about "Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers" @YosephRami

Published today! Dissecting tumor microenvironment heterogeneity in syngeneic mouse models: insights on cancer-associated fibroblast phenotypes shaped by infiltrating T cells frontiersin.org/articles/10.33… @CCITdk @FrontImmunol

#Postdoc position in Cancer #Immunotherapy 👉bit.ly/3RljEpZ You get all at once: 1️⃣ Exciting project in the most 🔥 topic (acquired resistance) 2️⃣ Access to ALL you need at fantastic @CCITdk 3️⃣ The most collaborative team on 🌍 bit.ly/3u5YLXO- with me as🧑‍✈️

PD-L1 status to select for ipilimumab+nivolumab in #melanoma 👉bit.ly/4aondV5 (Eur J Cancer) ✅ PD-L1≥1%: same outcome, regardless of combo or anti-PD-1 mono ✅ PD-L1<1%: improved PFS with combo Real-world, propensity score matched analysis of an entire-country cohort